Rani Therapeutics Holdings, Inc. (RANI) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.23
↓-71% vs avg
5yr avg: 4.23
30Y Low1.9·High11.2
ROE
↑
-131.9%
-3% vs avg
5yr avg: -128.3%
30Y Low-207%·High-31%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
RANI Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Rani Therapeutics Holdings, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $50M | $89M | $39M | $85M | $141M | $319M | — | — |
| Enterprise Value | $36M | $75M | $65M | $109M | $144M | $202M | — | — |
| P/E Ratio → | -1.72 | — | — | — | — | — | — | — |
| P/S Ratio | 30.91 | 54.68 | 37.95 | — | — | 117.55 | — | — |
| P/B Ratio | 1.23 | 2.15 | 11.17 | 3.33 | 1.90 | 2.63 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
RANI EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 45.92 | 63.19 | — | — | 74.32 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
RANI Profitability
Margins and return-on-capital ratios measuring operating efficiency
Rani Therapeutics Holdings, Inc. earns an operating margin of -2346.0%. Operating margins have expanded from -5186.2% to -2346.0% over the past 3 years, signaling improving operational efficiency. A negative ROE of -131.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 44.9% | 44.9% | 100.0% | — | — | 100.0% | 100.0% | 100.0% |
| Operating Margin | -2346.0% | -2346.0% | -5186.2% | — | — | -1899.1% | -3581.0% | -2764.6% |
| Net Profit Margin | -1817.1% | -1817.1% | -2920.0% | — | — | -306.6% | -3615.4% | -2716.8% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -131.9% | -131.9% | -207.5% | -68.3% | -31.3% | -202.5% | — | — |
| ROA | -62.3% | -62.3% | -63.5% | -40.9% | -26.3% | -8.2% | -32.6% | -115.5% |
| ROIC | -101.4% | -101.4% | -101.1% | -78.1% | -117.0% | -940.7% | — | — |
| ROCE | -122.2% | -122.2% | -159.9% | -86.3% | -56.5% | -52.7% | -35.3% | -138.6% |
RANI Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $19M exceeds total debt of $4M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | 8.51 | 1.18 | 0.41 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.34 | 7.43 | 0.95 | 0.04 | -0.97 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -13.25 | -13.25 | -10.24 | -13.00 | -58.08 | -112.83 | -133.42 | -2657.70 |
Net cash position: cash ($19M) exceeds total debt ($4M)
RANI Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Rani Therapeutics Holdings, Inc.'s current ratio of 4.21x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 6.36x to 4.21x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.21 | 4.21 | 1.50 | 6.36 | 20.96 | 45.30 | 14.12 | 4.84 |
| Quick Ratio | 4.21 | 4.21 | 1.50 | 6.36 | 20.96 | 45.30 | 14.12 | 4.84 |
| Cash Ratio | 3.92 | 3.92 | 1.39 | 6.08 | 20.45 | 44.49 | 13.76 | 4.73 |
| Asset Turnover | — | 0.03 | 0.03 | — | — | 0.02 | 0.01 | 0.04 |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 456.42 | 151.97 | — | — | — | 1358.87 | 93.21 |
RANI Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Rani Therapeutics Holdings, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $66M | $28M | $26M | $24M | $20M | $19M | $19M |
Peer Comparison
Compare RANI with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 RANIYou | $50M | -1.7 | — | — | 44.9% | -2346.0% | -131.9% | -101.4% | — |
 LNTH | $7B | 31.1 | 17.2 | 19.5 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 |
 NUVL | $9B | -21.1 | — | — | — | — | -36.7% | -32.5% | — |
 ARQT | $3B | -205.1 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 PRAX | $9B | -22.5 | — | — | — | — | -45.8% | -65.0% | — |
 CDTX | $7B | -8.3 | — | — | 100.0% | -13811.9% | -219.0% | — | — |
 TNGX | $3B | -32.8 | — | — | 96.3% | -178.4% | -37.2% | -38.5% | — |
 INVA | $2B | 6.9 | 6.8 | 8.5 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 NKTR | $1B | -6.8 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 AVXL | $235M | -4.7 | — | — | — | — | -43.1% | — | — |
 MNKD | $1B | 194.5 | 31.3 | 87.8 | 82.5% | 11.1% | — | 21.6% | 9.3 |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
RANI — Frequently Asked Questions
Quick answers to the most common questions about buying RANI stock.
What is Rani Therapeutics Holdings, Inc.'s P/E ratio?
Rani Therapeutics Holdings, Inc.'s current P/E ratio is -1.7x. This places it at the 50th percentile of its historical range.
What is Rani Therapeutics Holdings, Inc.'s ROE?
Rani Therapeutics Holdings, Inc.'s return on equity (ROE) is -131.9%. The historical average is -128.3%.
Is RANI stock overvalued?
Based on historical data, Rani Therapeutics Holdings, Inc. is trading at a P/E of -1.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Rani Therapeutics Holdings, Inc.'s profit margins?
Rani Therapeutics Holdings, Inc. has 44.9% gross margin and -2346.0% operating margin.